What Is Proteomics? Core Concepts, Technologies, and Applications
Proteomics is the large-scale study of proteins—their identities, abundances, structures, modifications, and interactions—within a biological sample. It answers questions that genomics alone cannot, because protein levels and states often diverge from what the underlying genes predict. This explainer covers the core concepts, the main technology routes (mass spectrometry, affinity-based assays, and high-plex spatial methods), the applications that matter most, and the practical constraints you should weigh before choosing an approach.
Proteomics vs. Genomics and Transcriptomics
Genomics reads DNA—the blueprint. Transcriptomics measures RNA—the working copies. Proteomics measures the proteins that actually carry out most cellular functions. Each layer adds information the previous one cannot supply.
| Layer | What it measures | Key limitation it leaves open |
|---|---|---|
| Genomics | DNA sequence, variants, copy number | Says nothing about whether a gene is expressed or how much protein is made |
| Transcriptomics | RNA abundance | RNA levels correlate imperfectly with protein levels; no direct readout of protein activity or modification |
| Proteomics | Protein identity, abundance, modifications, interactions | Requires sufficient sample quality and material; dynamic range is challenging |
The practical consequence: if you want to know whether a variant actually changes cell behavior, or whether a drug hits its intended target, you need protein-level measurement. As the McDonnell Genome Institute (MGI) frames it, its Functional Imaging hub exists for "variant elucidation"—connecting genetic changes to functional, protein-level outcomes.
Core Concepts in Proteomics
Protein abundance and dynamic range
Protein concentrations in a cell can span many orders of magnitude. High-abundance proteins (like albumin in blood) can mask low-abundance ones (like many signaling proteins and biomarkers). Most workflows include depletion, fractionation, or enrichment steps to manage this.
Post-translational modifications (PTMs)
Proteins are chemically modified after translation—phosphorylation, glycosylation, ubiquitination, and many others. These modifications control activity, localization, and stability. Deep-scale PTM analysis is a distinct capability; MGI's Mass Spectrometry Technology Access Center lists "Deep-scale PTM analysis" among its services.
Protein–protein interactions
Proteins rarely act alone. Interaction mapping reveals complexes, signaling networks, and drug targets. This is often done alongside abundance measurements rather than instead of them.
Spatial context
Knowing a protein is present in a tissue is different from knowing which cells contain it. Spatial methods preserve location information, which matters for tumor heterogeneity, tissue architecture, and biomarker validation.
Main Technology Routes
Mass spectrometry (MS)
MS identifies and quantifies proteins by measuring the mass-to-charge ratios of peptides (usually after enzymatic digestion). It is the most broadly unbiased route—you don't need to know in advance which proteins to look for.
Workflow in outline:
- Sample preparation — lyse cells or tissue, extract protein, digest into peptides.
- Separation — liquid chromatography separates peptides before they enter the instrument.
- Ionization and measurement — peptides are ionized and their masses measured; fragmentation gives sequence information.
- Data analysis — spectra are matched to sequences and quantified.
Expected result: a catalog of identified proteins with relative or absolute abundance, and optionally modification sites. MGI's Mass Spectrometry hub covers proteomics, metabolomics, lipidomics, deep-scale PTM analysis, native mass spectrometry, and spatial multi-omics MS technologies.
Affinity- and antibody-based assays
These use antibodies or other affinity reagents to detect specific proteins. They trade breadth for sensitivity and throughput—excellent when you know your targets. High-plex proteomics panels let you measure many proteins simultaneously from limited sample.
High-plex and spatial methods
High-plex proteomics and spatial multi-omics combine many-analyte measurement with location. MGI lists "High-throughput proteomics," "Single cell genomics," and "Spatial transcriptomics" under its Genome Technology Access Center, and "Spatial multi-omics MS technologies" under its Mass Spectrometry hub—reflecting how these approaches increasingly overlap.
Functional and imaging readouts
For connecting proteins to phenotype, functional imaging and massively parallel cellular screening (including drug screening and isolating live cells from specific phenotypes) provide a bridge. MGI's Functional Imaging hub lists these capabilities explicitly.
Applications
- Biomarker discovery — finding proteins that distinguish disease states, treatment responders, or disease stages.
- Drug target validation — confirming that a drug engages its intended protein target and measuring downstream effects.
- Clinical research — as MGI notes in its September 2025 piece, "research-grade data matters in clinical trials," especially with scarce or degraded patient material where analytical precision determines whether samples can be used at all.
- Multi-omics integration — combining proteomics with genomics and transcriptomics for a fuller picture. MGI describes itself as offering "a full suite of multi-omic services," and its June 2025 piece "Clinical OMICS: Where Multi-Omics Meets Clinical Reality" addresses how these technologies are moving toward clinical use.
- Variant elucidation — determining whether a genetic variant has functional consequences at the protein level.
Practical Constraints to Weigh
- Sample quality and quantity. Degraded or scarce material limits what any platform can detect. This is a recurring theme in clinical research contexts.
- Dynamic range. Without depletion or fractionation, low-abundance proteins can be invisible.
- Throughput vs. depth. High-plex panels give breadth and speed; deep MS workflows give depth and modification detail. You often cannot maximize both.
- Reproducibility. Batch effects, instrument drift, and sample handling all affect results. Research-grade standards and rigorous QC are not optional.
- Bioinformatics load. Proteomics datasets are large and require specialized computational analysis. MGI lists "Computational biology/bioinformatics" as a core capability within its Genome Technology Access Center—a signal that this is not an afterthought.
Choosing an Approach
If you need unbiased discovery across many proteins, start with mass spectrometry. If you have known targets and limited sample, affinity-based high-plex panels are often more practical. If spatial context matters—tumor architecture, tissue heterogeneity—prioritize spatial proteomics or spatial multi-omics. If the goal is linking a variant to function, pair proteomic measurement with functional screening or imaging.
MGI's own positioning is instructive: it emphasizes breadth of resources "in one location," with 16 years of average employee tenure, a 95% repeat partner rate, and current partnerships spanning 65 academic institutes and 56 biopharma partners. For teams that need multiple omic layers coordinated rather than outsourced piecemeal, that integration is the relevant selection criterion.
Where to Start
Define your biological question first, then let it dictate the technology. A biomarker discovery question, a target engagement question, and a variant function question each point to different platforms and sample requirements. MGI's project intake ("Start a Project") and its four technology hubs—Genome Technology Access Center, Genome Engineering & Stem Cell Center, Mass Spectrometry Technology Access Center, and Functional Imaging—map onto these distinct needs. Match your question to the hub, confirm sample requirements early, and plan the bioinformatics analysis before data generation begins.